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The aim of this study was to define the recommended dose of oxaliplatin when combined with infusional 5-fluorouracil (5-FU) and
concurrent pelvic radiotherapy. Eligible patients had inoperable rectal cancer, or symptomatic primary rectal cancer with metastasis.
Oxaliplatin was given on day 1 of weeks 1, 3 and 5 of radiotherapy. Dose level 1 was oxaliplatin 70mgm
 2 with 5-FU
200mgm
 2day
 1 continuous infusion 96hweek
 1. On dose level 2, the oxaliplatin dose was increased to 85mgm
 2. On dose level
3, the duration of the 5-FU was increased to 168h per week. Pelvic radiotherapy was 45Gray (Gy) in 25 fractions over 5 weeks with
a boost of 5.4Gy. Fluorine-18 fluoro deoxyglucose and Fluorine-18 fluoro misonidazole positron emission tomography (FDG-PET
and FMISO-PET) were used to assess metabolic tumour response and hypoxia. In all, 16 patients were accrued. Dose-limiting
toxicities occurred in one patient at level 2 (grade 3 chest infection), and two patients at level 3 (grade 3 diarrhoea). Dose level 2 was
declared the recommended dose level. FDG-PET imaging showed metabolic responses in 11 of the 12 primary tumours assessed.
Four of six tumours had detectable hypoxia on FMISO-PET scans. The addition of oxaliplatin to infusional 5-FU chemoradiotherapy
was feasible and generally well tolerated. For future trials, oxaliplatin 85mgm
 2 and 5-FU 200mgm
 2day
 1 continuous infusion
96hweek
 1 is the recommended dose when combined with 50.4Gy of pelvic radiotherapy.
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In the treatment of rectal cancer, concurrent chemoradiation with
5-fluorouracil (5-FU) improves both local control and overall
survival when compared with radiotherapy alone. Combined
modality treatment has been accepted as an integral part of the
pre- and postoperative treatment of rectal cancer (Pahlman and
Glimelius, 1990; Tveit et al, 1997). While advances in the planning
and application of radiotherapy have been made, as yet there have
been only small gains in chemotherapy. Protracted venous
infusion of 5-FU has been proven superior to bolus 5-FU when
combined with radiation (Krook et al, 1991; O’Connell et al, 1994).
Oxaliplatin is a novel platinum agent that has considerable activity
in colorectal cancer. With 5-FU and folinic acid, the combination
is synergistic producing response rates over 50% (Goldberg et al,
2004), leading to significant disease progression-free advantage in
the metastatic setting. Like other platinum derivatives, oxaliplatin
may also enhance tumour radioresponsiveness (Blackstock et al,
2000). Based on the synergism with 5-FU and its potential for
enhanced radiosensitisation, oxaliplatin could increase the efficacy
of infusional 5-FU when combined with radiation in the treatment
of locally advanced or inoperable rectal cancer. This combination
could theoretically provide superior local and systemic control of
disease, and thereby improve palliation and quality of life.
We conducted a two-centre, open-label, nonrandomised dose
escalation study investigating the feasibility of oxaliplatin com-
bined with concomitant 5-FU and radiotherapy in inoperable or
metastatic rectal cancer patients. The objective of this phase I trial
was to define the recommended doses of oxaliplatin when used in
this setting. Secondary exploratory objectives were assessment of
response rates at primary and metastatic sites, including correla-
tion of metabolic response by fluorine-18 fluorodeoxyglucose
positron emission tomography (FDG-PET) with conventional
imaging (computed tomography (CT)) response. The presence of
tumour hypoxia is recognised as an adverse prognostic factor in
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sother solid tumours treated with radiation (Nordsmark and
Overgaard, 1996). We also sought to determine by fluorine-18
fluoromisonidazole positron emission tomography (FMISO-PET)
if primary rectal tumours demonstrate imageable hypoxia.
MATERIALS AND METHODS
The trial was approved by the human research ethics committees
of the two participating centres, Peter MacCallum Cancer Centre
and Austin and Repatriation Hospital.
Eligibility criteria
Patients entering the study had histologically proven rectal
adenocarcinoma, either T3, T4, M0 deemed unresectable or any
T M1 requiring local treatment at diagnosis. No previous
chemotherapy or radiotherapy was allowed. The patient’s tumour
was to be within 15cm of anal verge. Patients were to be 18 years
or older, with an Eastern Cooperative Group (ECOG) score of 2 or
less. Haematologic, renal and liver function had to be adequate:
absolute neutrophil count X1500mm
 3, haemoglobin X100gL
 1,
platelets X150000mm
3, serum creatinine p1.25 upper limit of
normal, bilirubin p2.0 upper limit of normal and liver
transaminases less than twice the upper limit of normal. Written
informed consent was required. Patients were excluded from the
trial if they had a history of myocardial infarction within the
previous 6 months or unstable cardiac disease, history of other
malignancy (except nonmelanocytic skin cancer) peripheral
neuropathy, central nervous system metastases, pregnant or
lactating, psychiatric disorders or being treated with other
investigational agents.
Pretreatment evaluation
Pretreatment evaluation consisted of biopsy, digital rectal exam-
ination, rigid sigmoidoscopy, ECOG performance status, complete
medical history and physical examination 14 days prior to first
dose of the study drug. Complete laboratory results, abdominal
and pelvic CT and chest X-ray were also required. Some
participants were also assessed by FDG-PET and FMISO-PET
scans.
Radiotherapy
Pelvic radiotherapy was given with a megavoltage machine (6–
18MV), using a three- or four-field technique. The patient was
placed in prone position and a bellyboard was utilised to minimise
the amount of small bowel in the treatment field. The total
radiation dose was 50.4Gray (Gy) in 1.8Gy per fraction per day,
5 days per week. The first 45Gy was given to the pelvic field. The
final 5.4Gy was given to a boost field encompassing any gross
disease with a 2cm margin. The pelvic field was treated to a
planning target volume with upper border at the L5/S1 junction,
inferior border 3cm below the primary tumour or at the inferior
aspect of the obturator foramina, whichever was the most inferior,
lateral border at 1.5cm lateral to the widest bony margin of the
true pelvic side wall and posterior border at a minimum of 1cm
behind the anterior bony sacral margin. Treatment planning was
performed with computerised dosimetry. All fields were treated
daily.
Chemotherapy
Oxaliplatin (Exolatint, SanofiBSynthelabo) was administered as a
2-h infusion on day 1 of weeks 1, 3 and 5 of radiotherapy. Dose
level 1 was 70mgm
 2, and dose levels 2 and 3 was 85mgm
 2.
Infusional 5-FU was given as a protracted venous continuous
infusion via a peripherally inserted central catheter or implantable
device line by an ambulatory pump for 96h (5 daysweek
 1) at the
first two dose levels, or for 168h (7 daysweek
 1) at the third dose
level. The dose was 200mgm
 2day
 1. Patients could only receive
the oxaliplatin if they had X1500mm
 3 neutrophils and
X150000mm
 3 platelets.
Patient monitoring during study treatment
Patients were reviewed weekly during the course of chemoradia-
tion. Full haematological and biochemical profile were assessed
weekly during treatment. Toxicity was recorded by worse grades
experienced regardless of relationship to study drugs. Adverse
events were graded according to National Cancer Institute
Common Toxicity Criteria (NCIC version 2.0, 1999). Colony-
stimulating factors or other anticancer medication were not
permitted during the study.
Post-treatment follow-up
Post-treatment evaluations were performed at 4 weeks, 3 months
and 6 months after chemoradiation to document progress and
toxicity. Follow-up included clinical history, examination, haema-
tology and blood biochemistry assessments. Response was
assessed 4 weeks after the completion of chemoradiotherapy
according to World Health Organization (WHO) criteria by
conventional abdominal and pelvic CT, and also for some by
FDG-PET. Patients with potentially resectable disease following
treatment could proceed to surgery 4 to 6 weeks after completion
of chemoradiotherapy.
Study design, end points and definitions
This was a phase I dose escalation study, with toxicity being the
major end point. The aim of this study was to assess the tolerability
and feasibility of combining oxaliplatin with concomitant 5-FU
chemoradiation. The primary objective was to find a suitable
oxaliplatin dose level that could be recommended for subsequent
phase II trials.
Four dose level combinations were planned. Oxaliplatin was
planned at 70, 85 or 100mgm
 2. The highest administered dose
was the level at which two or more of the six patients experienced
dose-limiting toxicities (DLTs). The recommended dose was the
level below.
DLTs were defined as toxicity experienced during, and within
2 weeks following chemoradiotherapy. These were defined as:
grade 4 neutropenia (ANCo0.5 10
9l
 1) X5 days, grade 4
thrombocytopenia (platelet count o10 10
9l
 1), grade 3 throm-
bocytopenia (platelet count 10–49 10
9l
 1) with bleeding, febrile
neutropenia (38.51C or higher for more than 24h and neutrophils
o500mm
 3), grade 3 or 4 nonhaematological toxicity outside the
irradiated volume (excluding alopecia, grade 3 emesis and
anaemia), grade 3 lower gastrointestinal or genitourinary toxicity
or any grade 4 toxicity within the irradiation volume, or
interruption of radiotherapy for more than 1 week.
The rules of progression to the next dose level were: at least
three patients entered at each dose level. If no DLTs occurred,
escalation to the next dose level occurred. If there was one DLT in
the three patients, three additional patients were entered at this
dose level. If X2 of the six (two out three) patients had a DLT, no
further dose escalation took place.
FDG-PET and FMISO-PET imaging
Secondary objectives were to assess response at primary and
metastatic sites by CT and FDG-PET imaging. FDG-PET para-
meters included maximum standard uptake value (SUV) and
visual response score (qualitative metabolic responses), which
were graded as a complete metabolic response (CMR) or partial
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smetabolic response (PMR) by experienced nuclear medicine
physicians. A CMR was assigned for cases where activity within
the primary tumour site had decreased to be equal to or less than
adjacent soft tissue in the radiation treatment volume. Areas of
increased uptake in bowel segments proximal and distal to the
primary tumour site that demonstrated higher uptake than that
corresponding to the primary lesion were interpreted as radiation
proctitis. FDG-PET scans were performed after a fast of at least 6h,
with imaging at least 60min after radiotracer administration.
Positron emission tomography scans for tumour hypoxia (
18F
misonidazole) were performed at baseline and postcompletion of
study protocol in six patients. FMISO-PET scans were obtained 2h
after radiotracer administration. All PET imaging was performed
on a dedicated PET scanner (PENN-PET 300H; UGM Medical
System Inc., Philadelphia, PA, USA), with the data processed using
measured attenuation correction and iterative reconstruction.
Paired FDG- and FMISO-PET scans were coregistered.
FMISO-PET scans were interpreted qualitatively after coregis-
tration with the baseline FDG-PET scan. Tumours were classified
as having evidence of hypoxia if the site of known tumour on FDG
imaging had higher FMISO uptake than both cardiac blood pool
and normal bowel activity. It should be noted that there is colonic
excretion of this radiotracer that can render qualitative interpreta-
tion and assignment of regions of interest for SUV analysis
difficult.
Statistical methods
The response rates were calculated as percentages of all evaluable
patients who commenced treatment. In all, 95% confidence
intervals (CI) for response rates were estimated using the exact
probabilities of the binomial distribution. The vital status of each
patient was taken to be the vital status on the close-out date.
Overall survival was measured from the date of commencing
protocol treatment to the date of death from any cause.
Progression-free survival was measured from the date of
commencing protocol treatment to the date of first progression
(local, regional or distant) or death without previous progression.
Survival times were censored at the close-out date for patients who
were still alive.
Kaplan–Meier product-limit method was used to estimate
overall and progression-free survival. In all, 95% CI for the
percentage surviving at a particular time were calculated using
the logit transformation. S-plus statistical software was used for
the analysis.
RESULTS
In total, 12 males and four females with a median age of 65 years
were entered on this trial. In all, 15 patients (94%) had metastatic
disease and two patients (13%) had T4 rectal tumours. Patient
characteristics are listed in Table 1. The median follow-up time
period for all patients from the date of commencement of protocol
treatment was 17 months (range, 4–35 months).
Acute toxicity
Table 2 lists all the toxicities for the 16 patients treated. There were
three patients on dose level 1, seven patients on dose level 2 and six
patients on dose level 3.
At dose level 1, one patient went into urinary retention, which
was thought probably related to treatment. This patient required
catheter insertion.
At dose level 2, one patient was admitted with a grade 3 chest
infection, not associated with neutropenia. This patient required
intravenous antibiotics in hospital and recovered quickly over a
48-h period. This patient subsequently developed haematemesis
and melena associated with over anticoagulation with warfarin.
Despite normalisation of coagulation parameters, he had a sudden
cardiorespiratory arrest and died. No autopsy was performed.
Although it was unclear whether the toxicity was directly related to
treatment, a decision was made to consider this a DLT and expand
the cohort at this level. An additional patient was admitted with a
small bowel obstruction at dose level 2 after receiving 25Gy. At
laparotomy, the obstruction was found to be due to extensive
peritoneal disease outside the radiation field. This was thought to
be unrelated to treatment, and was hence not deemed to be a DLT.
He was taken off study and did not receive any further radiation.
As this patient received only 25Gy, it was decided to treat a
seventh patient on this dose level to ensure that there were six
patients who had completed treatment and were evaluable for
toxicity. No further DLTs were seen.
At dose level 3, two patients experienced DLTs. Two patients
had grade 3 diarrhoea and grade 3 dehydration. These resolved
following brief interruption of treatment and intravenous fluids.
Grade 3 nausea (one patient), vomiting (one patient), fatigue (one
patient), dysuria (two patients) and neurological parasthesia (one
case) were also reported. These toxicities quickly resolved. No
further escalation took place after dose level 3. Dose level 2,
oxaliplatin 85mgm
 2 and a 96-h continuous infusion 5-FU at
200mgm
 2 per 24h period, was deemed to be the recommended
dose level.
Table 1 Patient characteristics
Patients
Characteristics No. %
Age
Median 65 years
Range 32–81 years
Sex
Male 12 75
Female 4 25
ECOG performance status
01 6
11 0 6 3
25 3 1
Histology
Well differentiated 1 6
Moderately differentiated 8 50
Poorly differentiated 2 13
Mixed differentiation 3 19
Not specified 2 13
Stage
T3 13 81
T4 2 13
Tx 1 6
N0 2 13
N1 7 44
N2 6 38
M0 1 6
M1 15 94
Metastatic disease
Nil 1 6
Bone 1 6
Liver 11 69
Lung 5 19
ECOG¼Eastern Cooperative Group.
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Out of 16 patients, 14 received a total radiotherapy dose of 50.4Gy
with concurrent chemotherapy, one patient received 45Gy and
chemotherapy and one patient received 25Gy and chemotherapy.
One patient required a 2-day break from radiotherapy due to
perirectal pain. This was subsequently attributed to an anal fissure.
The infusional 5-FU was also ceased temporarily. The oxaliplatin
and infusional 5-FU doses were reduced in the two patients
experiencing grade 3 diarrhoea.
Efficacy
In all, 14 patients were eligible for assessment of response. Two
patients died within 2 weeks of completing the protocol, and hence
were not assessable. By CT criteria, in the radiation field, one
patient (7%) achieved a complete response (CR), 12 patients (86%)
had stable disease and one patient (7%) was not evaluable. On
clinical examination, one other patient had a CR but stable disease
by CT criteria. Outside the radiation field, there was one CR, one
partial response (PR) (response rate 15%; 95% CI, 2%, 45%), two
progressed and the rest had stable metastatic disease by CT
criteria.
We performed FDG-PET studies in 12 patients to explore the
utility of FDG-PET imaging in assessing response (Table 3). All
patients had FDG uptake in their primary tumours before
chemoradiotherapy. On qualitative FDG-PET visual responses, 11
of 12 patients had a response. There were six PMR, five CMR and
one was reported as no change. The mean baseline SUVmax before
treatment (SUV1) was 9.73 (range, 5.2–14.1) and the post-
treatment SUVmax (SUV2) averaged 3.6 (range, 1.4–7.35). The
mean percentage reduction in SUV values ([SUV1 SUV2/
SUV1] 100%) in the primary tumours was 61.1% (range, 32.8–
100%). Of the five patients who proceeded to surgery, two had
documented FDG-PET CMR and three PMR. However, all five had
residual microscopic disease pathologically.
With regard to the metastatic sites of disease, generally the
largest lesion was chosen for FDG-PET assessment (n¼11). All but
one known metastatic lesion was FDG avid, with a mean SUV1 of
7.0 (range, 4.7–10.2) pretreatment and a mean SUV2 post-
treatment of 5.5 (range, 2.6–8.1). The mean percentage reduction
for the metastatic lesions was 24.5% (range, 6.3–39%). By visual
response score, there were no CMR, four PMR and six reported as
unchanged. At the time of last follow-up, five of six patients
without a qualitative change in FDG uptake at metastatic sites had
died vs one of four who achieved a PMR.
Table 3 correlates FDG-PET and CT responses. While the
majority of rectal lesions were reported as unchanged on CT
criteria, all but one had definite metabolic responses on PET. In
one patient, there was evidence of progression in the primary
tumour on CT, but a PMR on FDG-PET. However, when the CT
was repeated 4 weeks later, it confirmed a responding lesion. Both
patients who had CRs on clinical examination or CT criteria also
achieved a CMR on FDG-PET.
Tumour hypoxia
Six patients were assessed for tumour hypoxia by baseline FMISO-
PET imaging using qualitative scoring. Four of six primary
tumours had detectable hypoxia at baseline scanning. Of the
metastatic lesions, five of six were hypoxic. One patient had a
nonhypoxic primary and hypoxic bone metastases on FMISO-PET
imaging. Owing to adjacent activity in bowel, it was difficult to
define a discrete region of interest for SUV calculation with the
Table 2 Toxicities in the Study Population (n¼16)
Dose level 1 (n¼3) Dose level 2 (n¼7) Dose level 3 (n¼6)
Toxicity
Oxaliplatin 70mgm
 2; 96h CI 5-FU Oxaliplatin 85mgm
 2; 96h CI 5-FU Oxaliplatin 85mgm
 2; 168h CI 5-FU
Grade 1 2 3 412341234
Haematologic
Leukopenia 1 00013002100
Neutropenia 1 00012010100
Thrombocytopenia 0 00010101000
Anaemia 2 10032103100
Infection (without neutropenia) 0 00000100000
Neurosensory
Parasthesia/dysthesia 2 00061004010
Gastrointestinal
Nausea 2 10050102100
Vomiting 1 00020100000
Diarrhoea 2 00015003120
Constipation 0 00002003200
Stomatitis 0 00011002000
Proctitis 0 10030001100
Genitourinary
Bladder spasms 1 11010001000
Dysuria 0 20041000320
Urinary frequency/urgency 1 20042000100
Other
Fatigue, malaise 1 10022003110
Radiation dermatitis 1 00031001500
Dehydration 0 00011000010
5-FU¼5-fluorouracil; CI¼confidence interval.
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FDG and FMISO studies often overlapping with normal colonic
activity. Accordingly, qualitative or semiquantitative analysis of
FMISO uptake in this region is likely to be significantly
compromised without reference to either anatomical (PET/CT)
or metabolic (FDG-PET) characterisation of tumoral limits and its
relationship to the bowel lumen.
Surgery
Five patients underwent surgery postchemoradiotherapy treat-
ment. Four patients could be completely resected, one patient had
involved margins. There were no pathological CRs seen. Of the five
patients, four had abdominal–perineal resections, and one had a
Hartmann’s procedure. One patient had a pelvic abscess post-
operatively requiring examination under anaesthesia and surgical
drainage. There were no other significant complications post-
resection.
Survival
The median overall survival was 12 months (95% CI, 8 to 418
months) with 88%(95% CI, 61–97%) surviving at 6 months and
45% (95% CI, 19–75%) surviving at 1 year. The median
progression-free survival time was 6 months (95% CI, 3–8
months) with 56% (95% CI, 32–72%) and 8% (CI, 1–41%)
surviving without progression at 6 and 12 months, respectively.
DISCUSSION
The addition of oxaliplatin to standard chemoradiotherapy with
5-FU was feasible, well tolerated and active in treating inoperable
and metastatic rectal cancer in this phase I trial. The acute
toxicities were acceptable and there were no cases of febrile
neutropenia. Most patients experienced tolerable neurotoxicity,
mainly of grade 1 severity, with one grade 3 case observed at the
third dose level. Dose level 2 of oxaliplatin at 85mgm
 2 day 1, 22
and 43 during radiotherapy combined with a 96-h continuous
infusion of 200mgm
 2 5-FUday
 1 was considered the recom-
mended dose.
Combined postoperative chemoradiotherapy with 5-FU has been
shown to decrease local recurrence rates and improve survival in
patients with Dukes’ B2 and C rectal cancer (Moertel, 1994).
Preoperative chemoradiation may result in less acute and long-
term toxicity and lower recurrence rates than postoperative
treatment (Camma et al, 2000; Sauer et al, 2004). Preoperative
radiotherapy may also permit subsequent surgery in tumours that
were initially unresectable or allow sphincter sparing surgery
(Swedish Rectal Cancer Trial, 1997). The addition of oxaliplatin to
Table 3 FDG-PET and CT imaging responses (n¼12)
Patient No.
Site of disease
assessed
Pretreatment
SUV1
4 weeks post-
treatment SUV2
% reduction
(1-SUV2/SUV1)
Qualitative
visual response CT response Status
1 Primary 11.39 6.9 39.4 PMR SD DoD
Liver 5.67 6.55 UN PD 4mo
2 Primary 6.43 2.99 53.5 PMR SD DoD
Liver 7.92 5.33 32.7 PMR SD 9mo
3 Primary 12 3.1 74.2 PMR SD DoD
Liver 10.2 8.1 20.5 UN SD 24mo
4 Primary 9.6 3.6 62.5 PMR SD DoD
Para-aortic node 7.9 4.8 39.2 UN PR 12mo
5 Primary 5.2 1.4 73.1 CMR CR AWD
Liver 4.7 4.4 6.3 PMR SD
6 Primary 14.1 7.35 47.9 PMR SD NED
7 Primary 10 4.5 55 CMR N/E AWD
Liver 5.2 4.3 17.3 PMR CR
8 Primary 13.6 5.41 60.2 CMR SD AWD
Liver NU NU SD
9 Primary 7.33 NU 100 CMR SD AWD
Bone 4.76 2.61 45.1 PMR SD
10 Primary 6.8 1.5 77.9 CMR N/E
a DoD
Liver 8.7 6.2 28.7 UN SD 11mo
11 Primary 13.8 5.9 57.2 PMR PD AWD
Liver 8.4 7.8 7 UN SD
12 Primary 7.3 4.9 32.8 UN SD DoD
Liver 6.7 5.1 23.8 UN SD 14 mo
Lung 2.6 2.4 7.7 UN SD
FDG-PET¼Fluorine-18 fluoro-deoxyglucose positron emission tomography; CT¼computed tomography; SUV: standardised uptake value; ND: not done; NU: no uptake; CMR:
complete metabolic response; PMR: partial/incomplete metabolic response; PD: progression; N/E: not evaluable. UN: unchanged metabolic response; AWD: alive with disease;
DOD: dead of disease; NED: no evidence of disease; mo: months.
aCR observed on clinical examination.
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chemoradiation, that is, increase the likelihood of downstaging
inoperable tumours, and sphincter sparing surgery could also be
better facilitated. For T4 tumours, results with conventional
chemoradiation with 5-FU are often unsatisfactory, and this group
has a high risk of developing distant disease (Janjan et al, 1999).
In patients with metastatic disease at diagnosis and local
symptoms, a regimen that could provide effective local and
systemic control, without significantly increasing the toxicity
profile would be good palliation in a group whose prognosis is
poor.
With regard to efficacy, although not the primary end point,
we have obtained some preliminary data about the response
in both the metastatic and primary lesions by FDG-PET
and CT imaging (Table 3). Response of rectal cancers to treatment
can be difficult to assess by conventional restaging. In the
12 patients who were assessed by FDG-PET, all had uptake in
their primary tumour. This is consistent with the literature
suggesting that most colorectal primaries are FDG avid (Blahd
et al, 1996). FDG uptake was also seen in all but one known
metastatic site.
Evaluation of therapeutic response on FDG-PET is not yet well
validated. The difficulties posed by semiquantitative measures of
FDG uptake such as the SUV is that activity in adjacent soft tissue
and bowel may increase following radiotherapy, presumably
reflecting an inflammatory response. Accordingly, we also used a
visual qualitative response score that incorporated an evaluation
not only of the intensity but also the pattern of uptake. Using a
threshold of a 25% reduction in SUV proposed by the EORTC
(Young et al, 1999), all 12 primary lesions would have been
classified as responding. On qualitative response scoring, there
were 11 out of 12 FDG-PET responses in the primary tumours
postcompletion of chemoradiation, compared to two out of 14 by
conventional restaging. The nonresponder on visual criteria had
an SUV reduction of 32.8%.
There is little in the reported literature about the prognostic
value of FDG-PET in rectal cancer. In one study, the post-
treatment SUV2 value was found to be more important
prognostically, rather than the SUV percentage reduction. Patients
with a primary tumour SUV2 greater than 3.2 after chemoradiation
were more likely to relapse (Oku et al, 2002). As with our previous
experience with the use of FDG-PET for therapeutic monitoring in
lung cancer (Kalff et al, 2001), the current study demonstrated that
a local CMR on PET was more common in the primary tumour
than a CR on conventional imaging. Although we have shown that
a CMR is prognostically significant in lung cancer patients
(Mac Manus et al, 2003), the lack of CMR in the metastatic
sites, which were present in the majority of patients, limits
assessment of the prognostic significance of a local CMR in our
cohort. Although both patients who achieved a local CMR and
subsequently had surgical resection still had residual miscroscopic
disease, this is not unexpected given the limitations of all imaging
modalities to detect small volume disease. Furthermore, it does not
necessarily imply that a CMR will not confer a prognostic
advantage compared to patients with only a partial or no metabolic
response. Further studies assessing the prognostic significance of a
local CMR in patients without disease outside the radiation
treatment volume are required to validate this technique as an
objective evaluation of local response. Nevertheless, our prelimin-
ary data suggest that FDG-PET may provide useful information
regarding both local and systemic response in combined modality
therapies.
Our FMISO-PET imaging results demonstrate that hypoxia can
be detected in some rectal cancers. There are few published studies
in this area (Wendling et al, 1984; Molls et al, 1994), none using
functional imaging, despite hypoxia being well established in other
malignancies as a significant obstacle to successful treatment with
radiation (Nordsmark et al, 1996). Technical limitations related to
high background activity in the normal colon need to be addressed
if semiquantitative evaluation of tumoral uptake were required.
Even for qualitative evaluation, clear delineation of the tumour
location is required. For our study, coregistration with an FDG-
PET study was used for this purpose, but with the advent of
combined PET/CT scanners, documentation of specific tumoral
uptake may be enhanced.
While the responses of the metastatic lesions seemed low by
conventional criteria, this was likely influenced by the cessation of
the treatment at 5 weeks, early restaging and the low cumulative
oxaliplatin dose received. In the original study by de Gramont (de
Gramont et al, 2000), which compared leucovorin and 5-FU with
or without oxaliplatin in the first-line setting for advanced disease,
the median time to response was seen at 9 weeks in the oxaliplatin
combination arm, and the oxaliplatin dose used was higher. Other
chemoradiation studies have varied in their cumulative oxaliplatin
dose. Freyer et al (2001) used oxaliplatin only on days 1 and 29
of treatment using dose escalations of 80, 100 and 130mgm
 2
with the MTD not being reached. Rodel et al (2003) used a cumu-
lative doseof240mgm
 2, with oxaliplatin administered days 1, 8, 22
and 29. Grade 3 diarrhoea was the DLT; the recommended dose
was 60mgm
 2. Aschele et al (2002) administered oxali-
platin 60mgm
 2 weekly with radiotherapy. Grade 3 diarrhoea
was the DLT, and 64% experienced grade 1 or 2 neurotoxicity.
Another study found the MTD of oxaliplatin to be 150mgm
 2
given days 2 and 30 with 5-FU and radiotherapy, with DLTs of
grade 3 diarrhoea and neurological toxicity (Sebag-Monefiore et al,
2002). Maintenance chemotherapy postcompletion of chemoradia-
tion should be explored in future studies in those who show
sensitivity to treatment as the higher cumulative doses received
may increase response rates at distant sites.
Our study is comparable to the results of other phase I and II
trials (Freyer et al, 2001; Carraro et al, 2002; Sebag-Monefiore
et al, 2002) assessing this combination, predominantly in the
locally advanced setting. There was no apparent increase in
complications seen in the five patients who underwent surgical
resection compared to other studies (Francois et al, 1999). No
significant late toxicity has been observed though follow-up is
short.
In conclusion, oxaliplatin combined with 5-FU infusional
chemoradiotherapy is feasible and well tolerated. The recommen-
ded doses are oxaliplatin at 85mgm
 2 days 1, 22 and 43 combined
with a 96-h continuous infusion 5-FU each week and concomitant
radiotherapy. In addition to a potential role in the preo-
perative setting for inoperable or locally advanced rectal cancer,
patients with metastatic disease and local symptoms may benefit
from this approach, and schedules including further cycles of chemo-
therapy should be explored.
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